Partnership will enhance physician awareness of START’s portfolio of trials, streamline referrals, and support patient access to early-phase oncology research
SAN ANTONIO, TX and BARCELONA, SPAIN — March 17, 2026 — The START Center for Cancer Research (“START”), the world’s largest community-based network of clinical trial sites specializing in early-phase oncology trials, today announced a strategic partnership with Trialing, a platform dedicated to connecting physicians and patients to clinical trials, helping physicians rapidly identify, evaluate, and refer patients to appropriate studies.
Through this exclusive collaboration,
START will work with Trialing across Europe to distribute curated information
on active oncology clinical trials, share real-time study updates, and notify
medical oncologists when enrollment slots become available through Trialing’s
physician network. The partnership is designed to streamline referrals, improve
awareness of trial opportunities, and ultimately expand patient access to
innovative cancer therapies.
“Access remains one of the greatest
barriers in oncology clinical research,” said Nick Slack,
MBE, Chairman and CEO of START. “Partnering with Trialing allows us to engage
physicians on a platform they already know and trust, provide clear and timely
visibility into our hundreds of active trials, and make it easier to connect
patients with START’s clinical trial sites across Europe. By reducing friction
in the referral process and increasing physician awareness of START, we advance
our mission of delivering hope through access.”
Trialing leverages innovative
technology, accurate data, and an agile, physician-focused approach supported
by its internal medical team to revolutionize how clinical trials are accessed.
By connecting physicians, patients, and the pharmaceutical industry through a
single platform, Trialing enables faster identification of appropriate studies
through structured clinical decision pathways and reduces barriers to trial
participation.
START’s European network of clinical
trial sites continues to grow, with a strong focus on accelerating early-phase
trials while maintaining deep relationships with referring physicians and
community oncologists. The collaboration with Trialing supports START’s mission
to bring innovative research closer to patients by improving transparency,
communication, and referral pathways.
“Clinical trial awareness and referral
efficiency are critical to advancing cancer care,” said Dr. Emiliano Calvo, President of START Europe. “By partnering
with Trialing, we can more effectively share study availability with medical
oncologists and ensure patients are referred at the right time, when enrollment
opportunities are open.”
“We’re proud to partner with START, an
organization that shares our commitment to improving access to clinical trials
through smarter, more connected solutions,” said Max Hardy-Werbin, CEO of Trialing. “Together, we’re
empowering physicians with the information they need to quickly identify
appropriate trials and helping patients reach innovative treatment options
without unnecessary friction.”
Trialing’s platform will enable START to
provide dynamic study updates, ensuring physicians have current information on
eligibility criteria and enrollment status, a key factor in reducing delays and
missed referral opportunities.
This partnership reflects a shared
vision to modernize clinical trial access, strengthen physician engagement, and
accelerate oncology research across Europe.
About START
About
Trialing Trialing
is a physician-driven platform focused on improving access to clinical trials
by connecting oncologists, hospitals, patients, and pharmaceutical sponsors
through structured trial intelligence and referral workflows. By combining
curated clinical trial data, clinical expertise from its medical team,
physician-centered discovery tools, and emerging AI-supported screening
capabilities, Trialing helps oncologists rapidly identify appropriate studies
and streamline referrals to recruiting research sites. Trialing supports a
growing network of oncologists and research centers across Europe and the
United States. Learn more at trialing.org.
Media Contacts: START: Lauren Panco, VP Marketing, lauren.panco@startresearch.com Trialing: Jonathan Gibbs, Chief
Product Officer, jgibbs@trialing.org
Deeply rooted in community
oncology centers globally, The START Center for Cancer Research provides access
to specialized preclinical and early-phase clinical trials of novel anti-cancer
agents. START clinical trial sites have conducted more than 1,000 early-phase
clinical trials, including for 50 therapies that were approved by the FDA or
EMA. START represents the world’s largest roster of early-phase principal
investigators across its 15 clinical trial sites. Committed to accelerating
passage from trials to treatments, START delivers hope to patients, families,
and physicians around the world. Learn more at STARTresearch.com.
